摘要
自1991年1月~9月,选择以顺铂为主的联合化疗方案(MAP、MVP、VP16+DDP等)治疗80例非小细胞肺癌。分为A、B二组,即60mg/M2(术后组)和90mg/M2(治疗组)。疗效评定:急性期(d1)枢复宁为95%,优于胃复安(57.5%);延缓期(d2~5)枢复宁为77.5%,胃复安为80%。枢复宁副作用是腹胀、便闭、大便干燥和肠蠕动增强,经对症治疗后均好转,未出现椎体外系反应。
Eighty patients with Non-Small cell lung cancer were treated by cisplatin (DDP) combined with scheme of chemotherapy (MAP,MVP,VP16+DDP,et al).A.B groups were divided with DDP 60mg/M2(Post-operated) and 90mg/M2(treated group) respectively. A group: d1 zofran 8mg+NS 50ml q8h or q 12h i.v. for 2 times, 15'each; DX 5mg iv(after zofran first time taken), then chemotherapy; d2~5 zofran 8mg tid po for four days.B group:d1 Metoclopramide 20mg q3h i.m. for four times,DX 5mg i.v.(after Metoclopramide first time taken), Then chemotherapy;d2~5 Metoclopramide 10mg tid po for four days. The evaluation of therapeutic effect: in acnte stage(d1): zofran was 95%(38/40)and excelled the Metoclopramide 57.5%(23/40); in delay stage(d2~5): zofran was 77.5%(31/40) and Metoclopramide 80%(32/40). Side effects of zofran were abdominal distension, constipation, dry stool and increased intestinal peristalsis. Zofran is a strong, highly selective antagonistic drug for 5HT8-acceptor with minimal side effect. It can prevent gastro-intestinal reaction during chemotherapy.
出处
《肿瘤》
CAS
CSCD
北大核心
1994年第2期88-90,共3页
Tumor
关键词
肺肿瘤
枢复宁
胃复安
Lung
cancer
Chemotherapy
Nausea and vomiting
Zofran Metoclopramide